Penserra Capital Management LLC Acquires Shares of 3,412 Charles River Laboratories International, Inc. $CRL

Penserra Capital Management LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 3,412 shares of the medical research company’s stock, valued at approximately $533,000.

Other large investors also recently made changes to their positions in the company. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the second quarter worth $29,000. Atlantic Union Bankshares Corp bought a new position in Charles River Laboratories International during the third quarter worth about $31,000. Geneos Wealth Management Inc. grew its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the period. Allworth Financial LP grew its position in shares of Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after buying an additional 190 shares during the period. Finally, SJS Investment Consulting Inc. bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $48,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $189.11 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The firm has a market cap of $9.31 billion, a price-to-earnings ratio of -121.22, a price-to-earnings-growth ratio of 5.67 and a beta of 1.63. The stock’s 50-day moving average is $204.33 and its 200-day moving average is $179.96. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays lifted their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Mizuho set a $215.00 price target on Charles River Laboratories International in a report on Friday, January 9th. Finally, Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.